DEA scheduling and criminal-law peptide landscape

A reader who has been told that "peptides are unregulated" or that "possession of peptide X is a federal crime" has been given one of two sentences that flatten a layered regulatory architecture into a slogan. The actual U.S. regulatory exposure around peptides is built from at least five structurally distinct legal regimes — the Federal Food, Drug, and Cosmetic Act, the Controlled Substances Act, the specific 21 U.S.C. § 333(e) statute that singles out human growth hormone, the FDA Personal Importation Policy, and the Rodchenkov Anti-Doping Act — each operating on a different definition of what is prohibited, who is liable, and what enforcement looks like in practice. None of these regimes is the same as FDA approval status, and confusing them is the most common error in peptide-legality discourse.

This dossier walks the architecture. The framing is informational. The page does not advise on legal action, does not recommend approaches to importation, and does not name suppliers. It documents the regulatory landscape so that decisions about peptide use can be made with the exposure in view. The companion regimes — competitive sport, compounding-pharmacy regulation — are covered in the WADA prohibited-status registry and the compounding pharmacy regulatory landscape respectively, and several specific framing claims about gray-market labeling are addressed in the research-only labeling misframing critic response.

1. The five regimes — what each one does and does not cover

The first analytic move is to separate the regimes that get conflated. A peptide can be FDA-approved for one indication, off-label-prescribed for another, distributed under a compounding-pharmacy exemption to FDA approval, sold under a research-use-only label outside the drug-regulation framework, prohibited under WADA for athletes, and either entirely uncontrolled, scheduled, or singled out by name in a unique criminal-penalty statute — and the answer to "is it legal" depends on which of those regimes the question is being asked under.

The Federal Food, Drug, and Cosmetic Act (FDCA, 21 U.S.C. § 301 et seq.) is the foundational drug-regulation statute. It governs whether a substance can be marketed as a drug for human therapeutic use; the new-drug-approval pathway under § 505, the bulk-substances framework under § 503A and § 503B for compounding, and the misbranding-and-adulteration prohibitions under § 331 are the load-bearing provisions. The FDCA's enforcement architecture is FDA-led with DOJ prosecution for criminal violations. Penalties for first-offense violations of § 331 are misdemeanor — up to one year imprisonment or fine, up to three years for repeat or fraud-intent violations (21 U.S.C. § 333(a)).

The Controlled Substances Act (CSA, 21 U.S.C. § 801 et seq.) is a separate statute that places specific substances on Schedules I through V based on abuse potential and accepted medical use. Possession, distribution, and manufacture of scheduled substances are criminal offenses under the CSA, with penalty scaling sharply by schedule. DEA is the enforcement agency. Most peptides on this site are not scheduled — the CSA does not have a peptide-class entry, and the closest scheduled-substance category to peptides is the Schedule III anabolic steroid bucket, which is structurally and pharmacologically distinct from peptide hormones.

The 21 U.S.C. § 333(e) human growth hormone provision is a unique criminal-penalty subsection embedded in the FDCA's penalties chapter rather than in the CSA. It singles out somatropin and its analogues by name and criminalizes off-label distribution. The statute is the operating reference for any conversation about somatropin's gray-market status and is the single most consequential peptide-specific criminal statute in U.S. law. Section 3 walks the provision in detail.

The FDA Personal Importation Policy (PIP) is a regulatory-discretion framework documented in FDA's Regulatory Procedures Manual Chapter 9-2 (FDA: Personal Importation Coverage Policy, RPM Chapter 9-2) that determines how FDA exercises enforcement discretion when individuals import unapproved drugs in personal-use quantities. The PIP is not a statute and does not confer a right to import; it documents the conditions under which FDA may decline to act on a personal-quantity importation. Customs and Border Protection (CBP) executes seizures at the border under FDA authority. Section 6 covers the framework.

The Rodchenkov Anti-Doping Act of 2019 (RADA, 21 U.S.C. § 2401–2404) is a federal criminal statute targeting persons who participate in doping schemes affecting major international sports competitions. The Act creates extraterritorial criminal jurisdiction over non-athletes — coaches, suppliers, doctors, kinesiologists — who provide prohibited substances to athletes competing in events with U.S. broadcaster, sponsor, or athlete participation. RADA carries up to 10 years' imprisonment and $250,000 personal / $1 million entity fines. The Eric Lira prosecution (covered in Section 8) is the first conviction under RADA and is the operative precedent for the statute's reach into the peptide market.

The framework's key non-overlap: a peptide outside CSA schedules and outside the § 333(e) HGH-specific statute can still be subject to FDCA misbranding-and-adulteration prohibitions, can still trigger Customs seizure at the border, and can still attract RADA prosecution if distributed in the context of a doping scheme. "Not scheduled" is not equivalent to "legal to distribute."

2. DEA scheduling — what is and is not scheduled

The Controlled Substances Act places substances on five schedules based on abuse potential, accepted medical use, and accepted safety. The categorical structure is well-documented; the operative reality for the peptide audience is that the vast majority of peptides on this site are not scheduled under any CSA schedule.

Schedule I — "high potential for abuse, no currently accepted medical use." Heroin, LSD, MDMA, psilocybin, marijuana (federally), and certain synthetic opioids are the canonical Schedule I substances. No peptide is on Schedule I.

Schedule II — "high potential for abuse, currently accepted medical use, abuse may lead to severe psychological or physical dependence." Opioid analgesics (oxycodone, fentanyl, morphine), most amphetamines, cocaine, and short-acting barbiturates dominate the schedule. No peptide is on Schedule II.

Schedule III — "moderate to low potential for physical and psychological dependence." This is the schedule that captures most anabolic-androgenic steroids. The Anabolic Steroids Control Act of 1990 (Pub. L. No. 101-647, the same omnibus crime bill that contained the § 333(e) HGH provision) placed anabolic steroids under Schedule III, and the Designer Anabolic Steroid Control Act of 2014 (DASCA, Pub. L. No. 113-260) expanded the list by approximately 25 named compounds plus a structural-similarity catch-all (Designer Anabolic Steroid Control Act of 2014, Wikipedia). Testosterone, nandrolone, oxandrolone, stanozolol, methyltestosterone, methenolone, and the prohormones (androstenedione and others) are the named Schedule III anabolic steroids (21 CFR 1308.13; Controlled Substances Act, Wikipedia).

Schedule IV — "low potential for abuse relative to Schedule III." Benzodiazepines, tramadol, modafinil, zolpidem are the canonical Schedule IV substances. No peptide is on Schedule IV.

Schedule V — "low potential for abuse relative to Schedule IV." Pregabalin, codeine cough preparations, and similar low-abuse-potential substances are scheduled here. No peptide is on Schedule V.

The DASCA structural-similarity language — "a drug or hormonal substance (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that is not listed and is derived from, or has a chemical structure substantially similar to a listed anabolic steroid, if it has been created with the intent of producing a substance that promotes muscle growth or causes a pharmacological effect similar to that of testosterone" — is a catch-all that captures novel small-molecule androgens. The "substantially similar chemical structure" test is read by the DEA and the courts against the steroid backbone, not against pharmacological effect alone. Peptide hormones are not steroidal; growth-hormone-releasing peptides, GHRH analogues, and ghrelin-receptor agonists do not have a steroid-substantially-similar chemical structure and are therefore not captured by DASCA's expanded scheduling, regardless of whether they affect muscle protein synthesis. This is a structural fact of the statute, not a regulatory oversight. As of May 2026, DEA has not invoked DASCA's catch-all against any peptide hormone, and there is no published rulemaking proposing to extend the steroid schedule to peptide GH-axis compounds.

The operative conclusion for the corpus: Possession of BPC-157, TB-500, ipamorelin, CJC-1295, MK-677 (ibutamoren, a nonpeptide GHS), hexarelin, GHRP-2, tesamorelin, sermorelin, AOD-9604, semaglutide, tirzepatide, liraglutide, retatrutide, melanotan-II, selank, semax, epitalon, dihexa, thymosin-alpha-1, MOTS-c, SS-31, PT-141, and the broader research-peptide corpus is not a federal CSA offense. Distribution may run into FDCA § 331 misbranding and unapproved-new-drug prohibitions; possession does not. The one peptide on this site that is singled out by name in a federal criminal statute — somatropin — is captured by 21 U.S.C. § 333(e) rather than by the CSA, and the § 333(e) regime is the subject of the next section.

3. 21 U.S.C. § 333(e) — the somatropin distribution statute

The single most consequential peptide-specific U.S. criminal statute is the human growth hormone provision at 21 U.S.C. § 333(e). The provision was added to the Federal Food, Drug, and Cosmetic Act in 1990 as part of the omnibus Crime Control Act of 1990 (Pub. L. No. 101-647), the same statute that placed anabolic steroids on Schedule III under the CSA. The somatropin provision was drafted as a parallel restriction operating through the FDCA rather than through the CSA — Congress declined to schedule somatropin under the CSA but elected to impose CSA-equivalent criminal penalties on off-label distribution through the FDCA penalties chapter.

The statutory text is precise. The version in force as of May 2026 reads:

Except as provided in paragraph (2), whoever knowingly distributes, or possesses with intent to distribute, human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition, where such use has been authorized by the Secretary of Health and Human Services under section 355 of this title and pursuant to the order of a physician, is guilty of an offense punishable by not more than 5 years in prison, such fines as are authorized by title 18, or both. (21 U.S.C. § 333(e)(1))

Three elements are load-bearing. First, the prohibited act is distribution (or possession with intent to distribute), not possession for personal use — a person who holds a vial of somatropin obtained for personal injection is not committing a § 333(e) offense by the holding alone. Second, the test is HHS-authorized indication, not FDA-approved drug — somatropin distribution falls outside § 333(e) only when the use is for an indication the HHS Secretary has authorized under § 505 (the FDCA's new-drug-approval section) and pursuant to a physician's order. The biohacker off-label indications (anti-aging, body composition, athletic recovery, longevity) are not HHS-authorized indications; somatropin distribution for those purposes is criminalized regardless of whether a physician's prescription is present. Third, the scope of "human growth hormone" is statutorily defined: "human growth hormone" means "somatrem, somatropin, or an analogue of either of them" (21 U.S.C. § 333(e)(4)). The analog clause is the operative coverage extension to the long-acting somatropins (somapacitan, somatrogon, lonapegsomatropin), which fall within the statute's reach by virtue of their structural derivation from somatropin.

The penalty structure is enhanced for distribution to minors: distribution of human growth hormone to an individual under 18 years of age is punishable by up to 10 years' imprisonment. The DEA is statutorily authorized to investigate offenses punishable under § 333(e) — the statutory cross-reference at § 333(e)(3) reads "The Drug Enforcement Administration is authorized to investigate offenses punishable by this subsection" — which is the structural reason DEA investigations of HGH distribution operate despite somatropin not being a CSA-scheduled substance. The FDA also exercises enforcement authority under § 333(e), typically in coordination with DEA for criminal-investigation pieces and with U.S. Attorney's Offices for prosecution.

FDA's interpretation of "distribution" under the statute extends to physician prescribing for unauthorized indications. The agency has taken the position, articulated in policy documents and commentary, that a physician who writes a prescription for somatropin for an off-label biohacker indication is engaged in "distribution" within the statute's meaning (Medical Justice: Anti-Aging Doctors and HGH Prescribing). The interpretation is contested by the anti-aging-medicine community but has not been definitively rejected by any appellate court; the operating posture for medical-board and FDA enforcement assumes the broad reading.

The prosecution record is sparse but established. The most direct § 333(e) prosecution on the record involves Neways, Inc., a Utah company. In September 2003, Neways pleaded guilty to knowingly selling approximately 100,000 bottles of "BioGevity," an oral spray product that contained somatropin (somatrotropin) distributed in violation of § 333(e). The conduct period ran from approximately March 1999 through April 2000. Neways stipulated to a $500,000 fine and forfeiture of $1.25 million in BioGevity proceeds. The case is a clean precedent — a finished-product manufacturer prosecuted for distributing somatropin under labeling that did not satisfy the HHS-authorized-indication test, with the corporate guilty plea and the criminal-forfeiture order on the docket. The Neways prosecution remains the most-cited example in legal commentary on § 333(e) enforcement because the case file documents the statute's operative reach to commercial distribution of an HGH product without an HHS-authorized indication.

The 2024 Eric Lira prosecution under the Rodchenkov Anti-Doping Act (Section 8) is the most recent significant federal action involving HGH distribution — Lira's conduct included importing and distributing somatropin (along with EPO) to Olympic athletes. The case was charged under RADA rather than § 333(e), reflecting prosecutorial preference for the doping-statute path when the sport-context predicates are met, but the underlying conduct is § 333(e)-eligible.

The practical implication of the statute's "distribution" focus. Federal enforcement of § 333(e) against individual personal users of somatropin is essentially nonexistent in the post-2000 record. The statute is structured to capture suppliers, prescribers operating outside HHS-authorized indications, and manufacturer-distribution networks; it is not structured to capture end-users injecting personal-quantity vials for personal use. This enforcement reality does not change the legal character of the conduct — possession with intent to distribute is the operative offense regardless of whether the intent is commercial or non-commercial — but it does shape the realistic regulatory exposure for personal-use somatropin protocols, which is meaningfully different from the exposure for distribution.

4. Federal Food, Drug, and Cosmetic Act violations beyond § 333(e)

The remaining peptides on this site — every peptide that is not somatropin or a somatropin analogue — fall outside § 333(e) but inside the general FDCA framework. The relevant provisions:

Section 331 (21 U.S.C. § 331) — prohibited acts. The FDCA enumerates 57 prohibited acts in § 331; the ones most relevant to peptides are the introduction of an unapproved new drug into interstate commerce (§ 331(d)), the introduction of an adulterated or misbranded drug (§ 331(a)), and the receipt in interstate commerce of an adulterated or misbranded drug (§ 331(c)) (21 U.S.C. § 331, Legal Information Institute). Distribution of a peptide that has not received FDA new-drug approval, for a human-therapeutic use, is an § 331(d) violation. Distribution of a peptide under labeling that misrepresents its identity, purity, or intended use is an § 331(a) or § 331(c) violation. These prohibitions apply to gray-market peptide distribution as a matter of statutory text.

Section 333(a) — misdemeanor penalty. A first-offense violation of § 331 is punishable by not more than one year imprisonment or a fine up to $1,000 or both. A repeat offense or an offense committed with intent to defraud or mislead is punishable by not more than three years imprisonment or a fine up to $10,000 or both (21 U.S.C. § 333(a)). The misdemeanor character is significant: § 333(a) is a "public welfare offense" that the Ninth Circuit has held does not require the government to prove the defendant's knowledge that the drug was misbranded — strict liability applies to the misbranding element, with knowledge required only of the conduct (Drug & Device Law Blog: Ninth Circuit Holds No Scienter Required for Misbranding, September 2023).

Practical reach to peptide distribution. Every commercial distribution of BPC-157, TB-500, KPV, selank, semax, epitalon, dihexa, MOTS-c, DSIP, melanotan-II, ipamorelin, CJC-1295, hexarelin, GHRP-2, AOD-9604, follistatin, IGF-1 LR3, and the other research peptides for human therapeutic use is an unapproved-new-drug distribution under § 331(d) and is FDCA-misdemeanor-eligible under § 333(a). The "research use only" label adopted by suppliers in the gray market is the regulatory-disclaimer strategy intended to position the product outside drug-regulation framing entirely; the label does not relieve a supplier of FDCA liability when the marketing context implies human use, and the research-only labeling misframing critic response addresses this dimension in more detail.

Why prosecution is rare for individual users. The misdemeanor structure of § 333(a), combined with the FDCA's primary focus on commercial-scale distribution rather than individual consumption, produces an enforcement landscape in which FDA enforcement against personal-use peptide possession is, as a practical matter, nonexistent. FDA's enforcement resources are directed at commercial distributors, repeat offenders, fraud-intent conduct (which moves to felony under § 333(a)(2)), and operations whose adverse-event signature has drawn agency attention. The 2025–2026 FDA enforcement focus has concentrated overwhelmingly on compounded GLP-1 telehealth platforms and on commercial-scale research-chemical suppliers, not on individual users — the September 2025 round of 30+ FDA warning letters to telehealth companies marketing compounded GLP-1s (FDA: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s) and the broader 55+ warning-letter round in September 2025 against GLP-1 compounders (Pharmaceutical Commerce: FDA Issues 30 Warning Letters to Telehealth Firms) are the operating pattern.

5. State pharmacy boards and state-level criminal statutes

The state-level regulatory layer is documented in more detail in the compounding pharmacy regulatory landscape dossier; the criminal-law dimension here is narrower. Most state-level regulation of peptide distribution operates through state pharmacy practice acts (administered by state boards of pharmacy with licensing-and-discipline sanctions) and state controlled-substances statutes (which generally mirror the federal CSA schedules with state-specific additions). The criminal exposure at the state level for peptide distribution is variable:

• California — among the strictest. The California State Board of Pharmacy enforces non-resident-pharmacy licensure aggressively, has applied state-level beyond-use-dating standards that shorten USP defaults, and prosecutes drug-misbranding and unapproved-new-drug distribution under state law in coordination with the California Attorney General's office.
• Texas, Florida, Arizona — historically lighter regulatory environments at the pharmacy-board level, with several large 503A operations and telehealth-and-compounding platforms based in these states during the 2022–2026 GLP-1 market.
• New York — the New York State Department of Health and the Education Department's Office of Professional Discipline handle pharmacy regulation; state-level peptide enforcement has tracked federal FDA activity rather than diverging substantially.

A few states have adopted state-specific controlled-substance scheduling that goes beyond the federal CSA — most relevantly, several states have scheduled SARMs (selective androgen receptor modulators) under state law even though SARMs are not federally CSA-scheduled, and a small number have adopted state-specific HGH-related restrictions that overlap with § 333(e). None of these have produced peptide-class scheduling at the state level as of May 2026.

The state-medical-board layer adds a parallel regulatory channel for prescribing physicians. A physician who prescribes off-label somatropin for biohacker indications faces medical-board disciplinary exposure under state medical-practice acts in addition to the federal § 333(e) exposure; medical boards in states with active anti-aging-clinic enforcement (California, New York, Massachusetts) have disciplined physicians for HGH prescribing outside HHS-authorized indications. For non-somatropin peptides, the medical-board exposure for prescribing physicians is more limited — the underlying substance is not a controlled drug, the prescription is for a compounded or research-channel product, and the disciplinary basis tends to track standard-of-care and informed-consent rules rather than peptide-specific prohibitions. Section 9 returns to the practitioner-liability question.

6. Customs, import alerts, and the Personal Importation Policy

Importation of peptides from international suppliers is regulated through a separate framework operating at the border. The FDA's Personal Importation Policy (PIP), documented in the agency's Regulatory Procedures Manual Chapter 9-2, sets out the conditions under which FDA may exercise enforcement discretion when individuals attempt to import unapproved drugs in personal-use quantities (FDA: Personal Importation Coverage Policy, RPM Chapter 9-2).

The four PIP conditions. Under the policy, FDA may decline to act on a personal-quantity importation when:

1. The drug is for the treatment of a serious medical condition for which effective treatment is not available domestically.
2. The drug is not commercially marketed or promoted to U.S. residents.
3. The drug is not considered to present an unreasonable risk.
4. The importer affirms in writing that the product is for personal use (generally a 90-day supply or less) and provides the name and address of the U.S.-licensed physician responsible for the importer's treatment, or evidence that the product is for continuation of a treatment begun in a foreign country.

The PIP is enforcement discretion, not a statutory right. FDA can detain any imported drug at any time for any reason; the PIP describes when the agency typically does not. The policy explicitly excludes commercial-scale importation, drugs that are commercialized to U.S. residents (which captures most peptides marketed by U.S.-facing online platforms even when shipped from overseas), and drugs the agency has determined present an unreasonable risk.

FDA Import Alerts and Detention Without Physical Examination (DWPE). The Import Alert system is the operational mechanism through which FDA flags specific products, manufacturers, or product classes for automatic detention at the border. A product on Import Alert can be detained by CBP without prior notice to the importer and without physical examination of the shipment — the "detention without physical examination" (DWPE) procedure (FDA Import Alerts landing page).

The peptide-specific Import Alert most relevant to the corpus is Import Alert 66-78, which covers unapproved drugs, including a growing list of peptides. The alert's coverage expanded in 2024–2025 to include additional unapproved peptides, with secondary-source reporting suggesting twelve additional peptides were added in 2025 (Peptide Examiner: The FDA's War on Peptides 2024–2026; The Peptide List: FDA Peptide Regulations Explained). For GLP-1 active pharmaceutical ingredients specifically, FDA launched a separate import alert in 2025 establishing a "green list" of FDA-vetted foreign API manufacturers, with non-green-list APIs subject to DWPE at the border (Frier Levitt: FDA Warning Letters and Hims-Novo Nordisk Deal).

Practical observations for personal importation. Personal importation of small-quantity peptides through international postal services has historically operated in a partial enforcement gap — FDA and CBP do not systematically intercept every personal-quantity peptide shipment, and the volume of postal-import traffic exceeds the inspection capacity at the major mail-import processing facilities. The trend since 2023 has been toward tighter enforcement, with the 2025 Amino Asylum action (June 2025 FDA action against a major gray-market research-chemical supplier, taking the operation offline) and the GLP-1 API import-alert framework signaling a more aggressive enforcement posture. The published-policy reality and the practical-enforcement reality have diverged for most of the 2010–2024 period; the 2024–2026 trend has narrowed that gap.

The "personal use" affirmation is not safe harbor. A common misunderstanding is that affirming personal use on an importation declaration insulates the importer from FDA action. The PIP is discretion, not entitlement: FDA can detain a personal-use-declared shipment, the importer's affirmation does not preempt FDA's authority, and false affirmations (representing commercial-scale importation as personal use) carry their own legal exposure under customs declarations statutes. The decision to permit a personal-use shipment is FDA's, made on a case-by-case basis under the agency's enforcement-discretion framework.

7. The WADA framework — separate from criminal law

The competitive-sport regulatory regime — covered in detail in the WADA prohibited-status registry dossier — is structurally separate from any of the criminal-law regimes covered on this page. WADA's Prohibited List operates on athletes subject to testing by national anti-doping organizations, sport federations, the military, or professional leagues that adopt WADA standards; the consequences are competition bans and disqualification of results, not criminal sanctions. A peptide can be WADA-prohibited and criminally legal (most of the research peptides), criminally restricted but not WADA-prohibited (the GLP-1 class as of 2026, on the WADA Monitoring Program but not yet prohibited), both, or neither.

The Rodchenkov Anti-Doping Act of 2019 is the federal criminal-statute bridge that links the WADA framework to U.S. criminal law for the supplier side. Section 8 walks the statute in detail. The structural distinction to keep in view is that WADA penalties are imposed by sport-governance bodies on athletes, while RADA penalties are imposed by U.S. federal courts on non-athlete suppliers; the two regimes can both attach to the same conduct or to neither, depending on the configuration.

8. The Rodchenkov Anti-Doping Act and the Eric Lira precedent

The Rodchenkov Anti-Doping Act of 2019 (Pub. L. No. 116-206, codified at 21 U.S.C. §§ 2401–2404) is the federal criminal statute that brings doping-scheme conduct within U.S. criminal jurisdiction. The statute is named for Grigory Rodchenkov, the former head of Russia's anti-doping laboratory who became the central whistleblower in the Russian state-sponsored doping disclosures of 2015–2016, and it was enacted in December 2020.

The Act's operative provision criminalizes participation in a "scheme in commerce" with the intent to influence "a major international sports competition" through the use of prohibited substances or methods. The penalty structure is up to 10 years' imprisonment, fines up to $250,000 for individuals or $1 million for entities, and mandatory restitution to scheme victims. The statute is structured to capture non-athletes — coaches, suppliers, doctors, kinesiologists, lab personnel — who participate in or enable doping schemes; athletes themselves are not the primary target of the criminal-penalty provisions, though the scheme's beneficiary structure can implicate athletes through other theories.

The Act includes a notable extraterritorial-jurisdiction provision: U.S. prosecutors can pursue cases for conduct occurring outside the United States, provided the major international sports competition affected has U.S. nexus through American athlete participation, U.S. broadcast rights, or U.S. sponsor involvement. The statute represents the first time a country has asserted criminal jurisdiction over doping conduct on a global scale, and WADA itself expressed reservations about the unilateral reach of the criminal regime (WADA Statement on Rodchenkov Act; Burnham & Gorokhov: What Is the Rodchenkov Anti-Doping Act of 2019).

The Eric Lira prosecution. The first conviction under RADA is the Eric Lira case in the Southern District of New York. Lira, a self-described "kinesiologist and naturopathic doctor" operating in and around El Paso, Texas, was charged in January 2022 with violating RADA in connection with a scheme to supply Olympic athletes with prohibited substances ahead of the Tokyo 2020 Olympic Games (held in 2021 due to the COVID-19 postponement). Lira pleaded guilty in May 2023; in February 2024, he was sentenced to three months' imprisonment plus supervised release.

The substances involved in the Lira scheme included human growth hormone (somatropin) and erythropoietin (EPO) — the two highest-profile WADA S2 substances and the two compounds most strongly associated with elite-sport doping enforcement in the post-2000 era. Lira obtained the substances from sources in Central and South America and imported them into the United States for distribution to athletes. Among the athletes who received substances through Lira's distribution were Nigerian sprinter Blessing Okagbare (who received a 10-year ban from the Athletics Integrity Unit in 2022) and Swiss sprinter Alex Wilson (named in Swiss media as having received materials from Lira) (U.S. Department of Justice: First Defendant Charged with Violating Anti-Doping Act Sentenced to Prison, February 2024).

Implications of the Lira precedent for the peptide market. The Lira case is the operating precedent for several features of RADA enforcement that the peptide community should read carefully. First, RADA is operational: the statute is being used, prosecutions are being filed, and convictions are being secured. Second, the prosecutorial path of choice for HGH distribution in a sport context is RADA rather than § 333(e), reflecting the broader sentencing range and the doping-scheme framing — but § 333(e) remains available for HGH distribution outside the sport-context predicates. Third, the international-sourcing dimension is captured: Lira's importation of HGH from Central and South America did not insulate him from U.S. prosecution because the downstream conduct (distribution to athletes competing in events with U.S. nexus) was the predicate. Fourth, the "kinesiologist / naturopathic doctor" framing of the supplier does not insulate from prosecution; the substance-and-intent elements are what the statute reaches.

The sociology of the peptide market intersects with RADA at the supplier-of-record question. Suppliers who distribute peptides primarily for biohacker and longevity indications are not direct RADA targets — the statute requires the major-international-sports-competition predicate. Suppliers whose customer base includes athletes in tested competition take on RADA exposure proportional to the demonstrability of that customer-base structure. The structural reality of the gray-market peptide channel — which sells the same vial to a biohacker, a recreational athlete, and a potentially-tested competitor without any verification of customer status — does not provide a safe-harbor structure for RADA exposure.

9. Practitioner liability — physicians, pharmacists, kinesiologists

The criminal-law landscape for clinicians and licensed practitioners is structurally different from the landscape for end-users, suppliers, and athletes.

Physician prescribing. A physician who writes a prescription for a peptide for a patient faces three distinct regulatory channels. First, the medical-board channel: state medical-practice acts permit boards to discipline physicians for prescribing outside the standard of care, for prescribing without an appropriate patient relationship, or for prescribing in ways that violate state-specific anti-aging-clinic regulations. Second, the federal channel: prescribing somatropin for an off-label biohacker indication is interpreted by FDA as "distribution" under § 333(e), with potential criminal exposure; prescribing a non-somatropin peptide for compounded preparation does not run into § 333(e) but operates within the compounding framework documented in the compounding pharmacy regulatory landscape dossier. Third, the malpractice channel: tort liability for adverse outcomes from peptide prescribing is independent of regulatory status and depends on the patient-specific informed-consent record, the standard-of-care reference, and the documented monitoring protocol.

The historical-enforcement record for physician peptide prescribing has been overwhelmingly administrative — medical-board discipline, FDA warning letters, professional-sanction proceedings — rather than criminal. The Eric Lira case is an exception to the general pattern, and the case's prosecution under RADA rather than under physician-prescribing statutes reflects Lira's quasi-clinician status and the doping-scheme predicate. A physician operating in a standard outpatient practice prescribing compounded peptides has faced primarily medical-board exposure through the 2010–2026 period; the criminal exposure has been latent rather than realized for the majority of prescribers.

Pharmacist dispensing. Pharmacists dispensing peptides face state-board-of-pharmacy disciplinary exposure for compliance with state pharmacy practice acts and federal exposure under the FDCA and the compounding-pharmacy statutes (503A/503B framework). The criminal exposure for pharmacists has historically tracked the New England Compounding Center prosecution model: pharmacists who operate compounding pharmacies in ways that cross the line into de facto manufacturing without FDA cGMP oversight face criminal-law exposure under federal racketeering, mail-fraud, and FDCA-felony statutes. Barry Cadden and Glenn Chin, the NECC senior pharmacists, received multi-year federal prison sentences under that framework (covered in the compounding pharmacy regulatory landscape dossier).

For routine 503A patient-specific peptide compounding, pharmacist criminal exposure is limited absent specific aggravating factors (mass-scale operations, mislabeling, adverse-event signals, repeated FDA warning letters ignored). For pharmacists dispensing somatropin to patients without HHS-authorized indications, § 333(e) exposure is theoretical rather than common — the prescription-receipt step has typically been treated as insulating the dispensing pharmacist from "distribution" liability when the prescription is from a licensed prescriber, with the prescriber-side liability operating as the regulatory focal point.

Kinesiologists, naturopaths, and unlicensed practitioners. Practitioners operating outside the licensed-prescriber framework — including kinesiologists, naturopaths in states without prescribing authority, fitness trainers, and the broader category of unlicensed health practitioners who recommend or supply peptides — face state-level unauthorized-practice-of-medicine exposure under state medical-practice acts in addition to FDCA exposure for unapproved-drug distribution. The Eric Lira case is the operative precedent here: a kinesiologist supplying performance-enhancing substances faced federal criminal prosecution under RADA, with the unauthorized-practice dimension operating as a contextual predicate. State-level enforcement against unlicensed practitioners has been variable, with periodic action against high-profile clinics and minimal action against the broader landscape.

10. Peptide-class-specific exposure summary

The corpus splits into classes with distinct regulatory exposure profiles:

Somatropin and its analogues — uniquely restricted. Somatropin, the long-acting somatropin analogues Sogroya/somapacitan, Ngenla/somatrogon, Skytrofa/lonapegsomatropin, and any future somatropin analogue fall under 21 U.S.C. § 333(e). Distribution for non-HHS-authorized indications is a 5-year federal felony (10 years for distribution to minors); DEA is statutorily authorized to investigate; the Neways prosecution is the operating precedent. Personal-use possession is not a § 333(e) offense.

Anabolic steroids — Schedule III CSA. Testosterone and its esters, nandrolone, oxandrolone, stanozolol, methyltestosterone, and the named DASCA-expansion compounds are Schedule III. This category is not peptides — it is included here only because anabolic steroids are routinely conflated with peptides in popular discourse and the two regulatory regimes are entirely distinct. Schedule III possession is a federal misdemeanor with prescription-defense available; distribution is felony.

Research peptides — FDCA-eligible, not CSA-scheduled. BPC-157, TB-500, KPV, ipamorelin, CJC-1295, hexarelin, GHRP-2, AOD-9604, MK-677, follistatin, IGF-1 LR3, thymosin-alpha-1, MOTS-c, DSIP, SS-31, PT-141, and the broader research-peptide class. Personal-use possession is not a federal criminal offense. Distribution is FDCA-misdemeanor-eligible under § 331/§ 333(a) with felony enhancement for fraud intent or repeat offenses. Import Alert 66-78 applies at the border. DEA enforcement is not the regime; FDA enforcement is, with state pharmacy boards adding state-level oversight.

Russian-tradition peptides — same FDCA framework, additional import scrutiny. Selank, semax, cerebrolysin, epitalon, and the broader category of peptides approved in Russia or Eastern Europe but not by FDA. The Russian approval status (Selank: 2009 anxiety indication; Semax: 2011 stroke and cognitive indications, included in Russia's List of Vital and Essential Drugs) does not exempt these peptides from U.S. FDCA exposure — FDA's unapproved-new-drug analysis is jurisdictionally U.S., and "approved in Russia" does not satisfy the FDCA test. Import Alert 66-78 generally captures this class, with Customs detention common for incoming international shipments.

GLP-1 receptor agonists — FDA-approved, with compounding-specific enforcement. Semaglutide, tirzepatide, liraglutide, exenatide, and the broader class. Off-label prescribing for weight management beyond label, for type-1 diabetes, or for cardiovascular-risk-reduction outside label indications is legal and routine; the prescription-validity step satisfies the FDCA framework. Compounded preparations are subject to the regulatory framework documented in the compounding pharmacy regulatory landscape dossier and the compounded GLP-1 equivalence myth critic response, with the 2024–2026 enforcement focus heavily concentrated on this class. International personal-importation of GLP-1 active pharmaceutical ingredients faces the green-list/import-alert framework FDA launched in 2025. Retatrutide, survodutide, mazdutide, cagrilintide and other investigational members of the class are subject to standard pre-approval FDCA prohibitions until approval status changes.

Melanocortin agonists — mixed. PT-141 / bremelanotide is FDA-approved (Vyleesi, 2019, for hypoactive sexual desire disorder in premenopausal women) and is therefore not in the FDA unapproved-new-drug bucket; off-label prescription is legal. Melanotan-II is unapproved, subject to FDCA exposure for distribution, and has a well-documented international supply chain that operates substantially outside the U.S. regulatory framework. The Melanocorp prosecution (2007 FDA warning letter, subsequent enforcement) is a documented precedent for melanocortin-agonist enforcement under the FDCA.

Khavinson bioregulator-class peptides. Epitalon, pancragen, and the broader Khavinson tetrapeptide class — Russian-origin, no U.S. approval, distributed as "parapharmaceuticals" in some jurisdictions. Same FDCA framework as the research-peptide class; the "parapharmaceutical" framing has no U.S. regulatory standing.

Insulin. Insulin is FDA-approved as a prescription drug class. Distribution requires a valid prescription per FDCA; no peptide-specific criminal-penalty statute applies. Pharmacy-board and standard prescription-drug regulations are the operative framework. The 2020 FDA reclassification of insulin as a biologic under the Biologics Price Competition and Innovation Act has structural implications for compounding (insulin compounding faced the same biologic-reclassification constraint as hCG); the criminal-law exposure dimension is essentially absent for personal possession.

11. The enforcement-pattern reality

The descriptive picture of who actually gets prosecuted for peptide-related federal offenses in 2024–2026 is more useful for risk assessment than the statutory exposure analysis alone. The patterns:

Federal prosecution of individual peptide users is essentially nonexistent. The published record for the post-2020 period contains effectively zero prosecutions of personal-use individuals for peptide possession. Federal enforcement resources are not directed at this layer of the market, and the statutory structure (FDCA misdemeanors, the § 333(e) focus on distribution, the RADA focus on schemes affecting major sport) does not capture personal users.

Prosecution of commercial-scale distributors of somatropin under § 333(e) is rare but happens. The Neways prosecution (2003 guilty plea, $500,000 fine, $1.25 million forfeiture) is the cleanest precedent. Subsequent § 333(e) enforcement has continued at a low cadence, generally targeting manufacturers and large-volume distributors of HGH products marketed for off-label indications.

Prosecution under RADA is new and operational. The Eric Lira sentencing in February 2024 established RADA as a prosecutorial tool. The statute's extraterritorial reach and its 10-year maximum sentence make it a more powerful enforcement option than § 333(e) where the sport-context predicates are met.

Compounding-pharmacy enforcement has accelerated dramatically in 2024–2026. The September 2025 FDA warning-letter rounds (55+ letters to GLP-1 compounders, 30+ to telehealth firms marketing compounded GLP-1s), the post-shortage-list litigation (OFA v. FDA on both tirzepatide and semaglutide, federal-court denials of preliminary injunctions in 2025), and the April 2026 FDA proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list together represent the most aggressive enforcement push against compounded peptides in the post-DQSA era. The compounding pharmacy regulatory landscape dossier covers this in detail.

Customs and import enforcement has tightened. FDA Import Alert 66-78 expansion in 2025, the GLP-1 API green-list framework, and the June 2025 action against Amino Asylum (one of the larger gray-market research-chemical platforms taken offline) signal a more aggressive border-enforcement posture. Individual personal-quantity importations still pass through the system at non-trivial rates, but the enforcement-discretion gap that defined the 2010–2024 period has narrowed.

State pharmacy-board enforcement varies but is generally tightening. California, Texas, Florida, and New York have all increased state-level enforcement of compounding-pharmacy regulations during 2024–2026, with telehealth-prescribing rules and state-specific peptide restrictions becoming more common (Frier Levitt: Regulatory Status of Peptide Compounding in 2025).

12. International context

The U.S. regulatory architecture is jurisdiction-specific. The peptide market is global, supply chains routinely cross borders, and the regulatory regime applicable to any given vial depends on where it was manufactured, where it was shipped to, where it was administered, and the jurisdiction-of-residence of the user. The major international frameworks:

United Kingdom. HGH is a Class C controlled drug under the Misuse of Drugs Act 1971, listed under Schedule 4 (Part II) of the Misuse of Drugs Regulations 2001. Class C status is the lowest tier of the UK controlled-drugs framework; under Schedule 4 (Part II), possession of HGH for personal medical use is not an offense, but supply, distribution, or sharing without authorization is a criminal offense. The peptide-broader market in the UK is regulated through the Medicines and Healthcare products Regulatory Agency (MHRA), with prescription-only medicine (POM) classifications applying to most therapeutic peptides (is-this-legal.com: Is HGH Legal in the UK 2026; verifiedhgh.uk: HGH UK law).

European Union. Regulation is country-by-country with EMA-level coordination for licensed medicines. The German, Dutch, and Scandinavian regulators operate among the tighter regimes; Eastern European member states have historically operated more loosely. The compounding-pharmacy framework varies similarly. There is no EU-level peptide-specific criminal statute analogous to § 333(e); HGH and the GH-axis peptides are regulated through standard prescription-only-medicine frameworks under member-state law.

Australia. The Therapeutic Goods Administration (TGA) regulates peptides primarily under the Poisons Standard. Most research peptides — including BPC-157, ipamorelin, CJC-1295, TB-500, and the broader class — are classified Schedule 4 (prescription-only medicine) under the Poisons Standard, with a February 2022 final decision by the TGA placing BPC-157 and a number of other popular peptides into Schedule 4 explicitly (Optimized Performance: Peptide Legal Status in Australia). Schedule 4 status means peptides are illegal to sell or import for human use without prescription authorization or Special Access Scheme Category B approval. Australian enforcement against gray-market peptide supply has tightened substantially since 2022.

Russia and Eastern Europe. Several peptides on this site are approved or registered for therapeutic use in Russia: Selank for generalized anxiety disorder (approved 2009), Semax for stroke and cognitive disorders (approved circa 2000s, added to Russia's List of Vital and Essential Drugs in 2011), and the Khavinson bioregulator class (registered as parapharmaceuticals through the Institute of Bioregulation and Gerontology). The Russian approvals do not satisfy U.S. FDCA requirements and do not affect U.S. regulatory exposure; for users in Russia and CIS countries, these peptides operate within a different regulatory framework than U.S. or EU users encounter.

China. The National Medical Products Administration (NMPA) has approved several incretin-class peptides not yet FDA-approved or with different regulatory standing in China. Cross-border supply of peptides from Chinese manufacturers — both legitimate API suppliers and gray-market product channels — is a major source for the global peptide market, including substantial U.S.-bound supply. The 2025 GLP-1 API green-list framework FDA established is the agency's direct response to this supply structure.

Other jurisdictions. Vary widely. Cross-border consumer importation of peptides operates across regulatory regimes that do not always align; the chain of regulatory accountability is often broken when supply originates in one jurisdiction, is shipped through transshipment hubs, and is received in another. The U.S. framework reaches the receiving end through Customs and Import Alert enforcement but cannot reach upstream into manufacturing operations in non-cooperating jurisdictions.

13. What this page does not do

This dossier documents regulatory exposure. It does not advise on legal strategy or recommend approaches to peptide acquisition, importation, distribution, or use; does not recommend specific suppliers (the site's vendor-mention prohibition applies); does not endorse or condemn the regulatory regime; and does not provide legal counsel. The regulatory landscape covered here is a moving target — statutes change, enforcement priorities shift, agency interpretations evolve. Decisions about peptide use that involve material legal exposure — supply, distribution, importation at scale, supplying athletes in tested competition, prescribing outside HHS-authorized indications — require qualified legal counsel familiar with the specific facts. The conservative position for any reader facing a question with criminal-law implications is to consult a licensed attorney with experience in FDA, DEA, controlled-substance, and pharmacy-regulation matters before acting, not to rely on this or any other secondary source.

Sources cited

External statutory and regulatory references:

• 21 U.S.C. § 333 — Penalties (FDCA), Legal Information Institute — § 333(a) misdemeanor penalty structure and § 333(e) human growth hormone criminal provision
• 21 U.S.C. § 331 — Prohibited acts (FDCA), Legal Information Institute — the 57 prohibited acts under the FDCA
• Controlled Substances Act, Wikipedia — CSA scheduling structure and Schedule III anabolic steroids
• 21 CFR Part 1308, eCFR — DEA scheduling regulations
• Anabolic Steroids Control Act of 1990, Wikipedia — 1990 omnibus crime bill placing anabolic steroids on Schedule III and adding § 333(e)
• Designer Anabolic Steroid Control Act of 2014, Wikipedia — DASCA expansion and structural-similarity catch-all
• Federal Register: Implementation of the Designer Anabolic Steroid Control Act of 2014, August 2023 — DEA implementing regulations
• FDA: Personal Importation Coverage Policy, RPM Chapter 9-2 — personal-importation enforcement-discretion framework
• FDA Import Alerts Landing Page — Import Alert framework and DWPE procedure
• DEA Diversion Control: Drug Scheduling — categorical structure and substance lists
• Rodchenkov Anti-Doping Act of 2019, Congress.gov H.R. 835 — federal statute creating doping-scheme criminal liability
• U.S. Department of Justice: First Defendant Charged with Violating Anti-Doping Act Sentenced to Prison, February 2024 — Eric Lira sentencing and case facts

External legal and regulatory commentary:

• HGH Controversies, Wikipedia — historical settlements (Genentech 1999, Serono 2005, Pfizer 2007) and § 333(e) enforcement context
• Medical Justice: Anti-Aging Doctors and HGH Prescribing — FDA interpretation of "distribution" under § 333(e)
• Burnham & Gorokhov: Rodchenkov Anti-Doping Act Overview — RADA scope and extraterritorial-jurisdiction provisions
• Drug & Device Law Blog: Ninth Circuit on Misbranding Scienter, September 2023 — public-welfare-offense framework for § 333(a) misdemeanors
• Council for Responsible Nutrition: Designer Anabolic Steroid Control Act of 2014 — DASCA scope analysis
• Frier Levitt: Regulatory Status of Peptide Compounding in 2025 — current peptide compounding enforcement environment
• Frier Levitt: FDA Warning Letters and Hims-Novo Nordisk Deal — GLP-1 API green-list framework
• Pharmaceutical Commerce: FDA Issues 30 Warning Letters to Telehealth Firms Over Compounded GLP-1 Marketing — September 2025 warning-letter round
• FDA: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s — agency announcement
• WADA Statement on Passage of the Rodchenkov Anti-Doping Act — international reaction to RADA

International framework references:

• is-this-legal.com: Is HGH Legal in the UK 2026 — UK Class C and Schedule 4 (Part II) regulatory framework
• Optimized Performance: Peptide Legal Status in Australia — TGA Schedule 4 classification of peptides including BPC-157

In-corpus cross-references:

• Somatropin peptide page — central § 333(e) reference molecule
• Long-acting somatropin peptide page — somapacitan/somatrogon/lonapegsomatropin captured by § 333(e) analog clause
• Insulin peptide page — biologic-reclassification framework
• WADA prohibited-status registry dossier — competitive-sport regulatory overlay
• Compounding pharmacy regulatory landscape dossier — 503A/503B and bulks-list framework
• Compounded GLP-1 equivalence myth critic response — bioequivalence framing
• Research-only labeling misframing critic response — RUO label regulatory standing